

UNIVERSIDAD MAYOR DE SAN SIMÓN
 FACULTAD DE MEDICINA
 INVENTARIO: Biblioteca "Julio Rodríguez Rivas"

07	13	01	101	597939
Código de Inventario				
03	11	09	Bs.	8-
Día		Mes		Año
				Valor

Contents

Glossary

v

Abbreviations

viii

1. Introduction	1
1.1 Background	1
1.2 Objectives and target audience	2
1.3 Methods used in developing the guidelines and recommendations	3
2. The clinical disease	5
3. Treatment objectives	7
3.1 Uncomplicated malaria	7
3.2 Severe malaria	7
4. Diagnosis of malaria	8
4.1 Clinical diagnosis	8
4.2 Parasitological diagnosis	9
4.3 Where malaria transmission is low-moderate and/or unstable	10
4.4 In stable high-transmission settings	10
4.5 Malaria parasite species identification	11
4.6 In epidemics and complex emergencies	11
5. Resistance to antimalarial medicines	12
5.1 Impact of resistance	12
5.2 Global distribution of resistance	12
5.3 Assessing resistance	13
6. Antimalarial treatment policy	14
6.1 Assessment of <i>in vivo</i> therapeutic efficacy	14
6.2 Criteria for antimalarial treatment policy change	15
7. Treatment of uncomplicated <i>P. falciparum</i> malaria	16
7.1 Assessment	16
7.2 Antimalarial combination therapy	16
7.3 The choice of artemisinin based combination therapy options	20
7.4 Practical aspects of treatment with recommended ACTs	23
7.5 Incorrect approaches to treatment	26
7.6 Additional aspects of clinical management	27
7.7 Operational issues in treatment management	29
7.8 Management of treatment failures	31
7.9 Treatment in specific populations and situations	32
7.10 Coexisting morbidities	38

8.	Treatment of severe falciparum malaria	41
8.1	Definition	41
8.2	Treatment objectives	41
8.3	Clinical assessment	42
8.4	Specific antimalarial treatment	42
8.5	Practical aspects of treatment	47
8.6	Follow-on treatment	48
8.7	Pre-referral treatment options	49
8.8	Adjunctive treatment	51
8.9	Continuing supportive care	53
8.10	Additional aspects of clinical management	54
8.11	Treatment during pregnancy	58
8.12	Management in epidemic situations	59
8.13	Hyperparasitaemia	60
9.	Treatment of malaria caused by <i>P. vivax</i>, <i>P. ovale</i> or <i>P. malariae</i>	62
9.1	Diagnosis	62
9.2	Susceptibility of <i>P. vivax</i> , <i>P. ovale</i> and <i>P. malariae</i> to antimalarials	63
9.3	Treatment of uncomplicated vivax malaria	63
9.4	Treatment of severe vivax malaria	66
9.5	Treatment of malaria caused by <i>P. ovale</i> and <i>P. malariae</i>	66
9.6	Monitoring therapeutic efficacy for vivax malaria	66
10.	Mixed malaria infections	68
11.	Complex emergencies and epidemics	69
11.1	Diagnosis	69
11.2	Use of rapid diagnostic tests in epidemic situations	69
11.3	Management of uncomplicated malaria in epidemics	70
11.4	Areas prone to mixed falciparum/vivax malaria epidemics	70
11.5	Use of gametocytocidal drugs to reduce transmission	71
11.6	Anti-relapse therapy in vivax malaria epidemics	71
11.7	Mass treatment	71
Annexes		
Annex 1.	The guidelines development process	77
Annex 2.	Adaptation of WHO malaria treatment guidelines for use in countries	83
Annex 3.	Pharmacology of antimalarial drugs	87
Annex 4.	Antimalarials and malaria transmission	133
Annex 5.	Malaria diagnosis	147
Annex 6.	Resistance to antimalarials	155
Annex 7.	Uncomplicated <i>P. falciparum</i> malaria	185
Annex 8.	Malaria treatment and HIV/AIDS	198
Annex 9.	Treatment of severe <i>P. falciparum</i> malaria	207
Annex 10.	Treatment of <i>P. vivax</i> , <i>P. ovale</i> and <i>P. malariae</i> infections	225
	Index	240